<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694561</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100223</org_study_id>
    <nct_id>NCT03694561</nct_id>
  </id_info>
  <brief_title>Developing a Management Approach for Patients With &quot;Late-Onset&quot; Pompe Disease</brief_title>
  <official_title>Developing a Management Approach for Patients With &quot;Late-Onset&quot; Pompe Disease GAA Variant Identified by Newborn Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study with no study related treatment of interventions. The purpose
      of the study is to investigate and document disease specific clinical symptoms in newborns
      and infants with Pompe disease without cardiomyopathy identified in newborn screening(NBS).
      There will be a baseline, 6 month and 12 month visit.

      The study has three goals:

        1. To study and record disease specific clinical symptoms in newborns and infants with
           Pompe disease without cardiomyopathy (disease of the heart muscle) identified through
           newborn screening (NBS)

        2. To devise an approach to characterize early musculoskeletal (muscles and joints)
           involvement in subjects with the &quot;late-onset&quot; GAA variant identified by NBS

        3. To determine criteria to start preventative therapies including enzyme replacement
           therapy (ERT) in patients with clinical features of Pompe disease identified via NBS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Late-Onset Pompe Disease(LOPD) is an inherited disorder caused by lack of or defect in the
      enzyme acid alpha-glucosidase (GAA). GAA enzyme deficiency causes glycogen to build up and
      damage cells throughout the body, especially in the heart and muscles. In LOPD, subtle and
      overt disease-specific features may go unrecognized in childhood without vigilant clinical
      examination and assessments with appropriate functional tests. In our clinical experience,
      children with the &quot;late-onset&quot; GAA variant may present much earlier in life and adult
      patients with LOPD consistently report a much earlier symptom onset and a significant
      diagnostic delay. These patients have shown improvement after initiation of ERT but have
      motor impairments adversely affecting their quality of life and growth from early childhood.
      Therefore, earlier diagnosis and initiation of ERT is crucial in these patients. Instituting
      ERT at an ideal time may prevent/reduce these irreversible musculoskeletal impairments and
      lead to a better quality of life and less disease burden as these children age.

      Our team of Pompe disease experts will perform detailed clinical evaluations, physical
      therapy evaluations, cardiac assessments, speech and swallow evaluations, biochemical tests,
      sleep questionnaire, and hearing assessments on these patients. These assessments will allow
      use to capture and describe the earlier clinical phenotype in these patients and provide
      insights into the early signs and symptoms of LOPD.This study will provide and evidence-based
      approach to clinical management of newborns with LOPD to primary care physicians and
      geneticists, leading to improves patient outcomes.

      The investigators will enroll 40 infants at Duke that has screened for LOPD. This study
      involves minimal risk to the patient and offers a potential benefit of improved disease
      management. The initial visit will be as soon as possible after a confirmed LOPD diagnosis
      and follow up visits will be at 6 and 12 months. The investigators will continue to gather
      clinical information on patients and monitor clinical status beyond assessment at three time
      points.

      The study has three goals:

        1. To study and record disease specific clinical symptoms in newborns and infants with
           Pompe disease without cardiomyopathy (disease of the heart muscle) identified through
           newborn screening (NBS)

        2. To devise an approach to characterize early musculoskeletal (muscles and joints)
           involvement in subjects with the &quot;late-onset&quot; GAA variant identified by NBS

        3. To determine criteria to start preventative therapies including enzyme replacement
           therapy (ERT) in patients with clinical features of Pompe disease identified via NBS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document subtle musculoskeletal signs of Pompe disease.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested individually by a formal physical therapy assessment, Alberta Infant Motor Scale (AIMS), Gross Motor Functional Measure (GMFM), Hammersmith Functional Motor Scale Expanded(HFMSE),Modified Hammersmith Functional Motor Scale Extend(MHMFS-EXTEND), and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders(CHOP INTEND) to give a combined assessment score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document Pompe-specific clinical symptoms.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested individually by physical examination, nutritional evaluation and functional assessment to give a combined analysis of Pompe-specific symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document elevation in Pompe-specific biomarkers from blood and urine samples.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested by comparing lab results to lab-specific ranges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document sleep quality.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested qualitatively by questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document auditory capacity.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested individually by visual reinforcement audiology (VRA) and distortion product optoacoustic emissions (DPOAE) to give a combined assessment score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document cardiac involvement.</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be analyzed by echocardiogram and electrocardiogram results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document muscle architecture of the calves, para-spinal muscles and tongue</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested qualitatively by simple ultrasound examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical records will be tracked for 1.5 years to document speech and swallow progression</measure>
    <time_frame>1.5 years</time_frame>
    <description>This outcome measure will be tested individually by using videofluoroscopic study, Preschool Language Scale-Fourth Edition(PLS4), Receptive-Expressive Emergent Language Test Third Edition(REEL3), Pediatric Eating Assessment Tool (PEDI EAT-10), Functional Oral Intake Scale(FOIS) and serial photographs to give a combined assessment score.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pompe Disease</condition>
  <condition>Pompe Disease (Late-onset)</condition>
  <condition>GAA Deficiency</condition>
  <arm_group>
    <arm_group_label>Late-Onset Pompe disease</arm_group_label>
    <description>Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy</description>
    <arm_group_label>Late-Onset Pompe disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who have been diagnosed with Late-Onset Pompe Disease via Newborn Screening
        (NBS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has been diagnosed via newborn screening

          -  Subject has a confirmed and documented diagnosis of Pompe disease and absence of
             cardiac involvement

          -  Subject has predicted &quot;late-onset&quot; GAA variants such as c.-32-13T&gt;G, c.2188G&gt;T,
             c.1935C&gt;A, c.1726G&gt;A, c.118C&gt;T etc. in homozygosity or compound heterozygosity

          -  Subject must be between 3 and 20 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>20 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya Kishnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Austin, MS,MA</last_name>
    <phone>9196681347</phone>
    <email>stephanie.austin@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet Blount, BA</last_name>
    <phone>9196817962</phone>
    <email>janet.blount@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Blount, BA</last_name>
      <phone>919-681-7962</phone>
      <email>janet.blount@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Priya Kishnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Dearmey, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013 Aug;54(4):219-27. doi: 10.1016/j.pedneo.2013.03.009. Epub 2013 Apr 28. Review.</citation>
    <PMID>23632029</PMID>
  </reference>
  <reference>
    <citation>Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009 Dec;124(6):e1116-25. doi: 10.1542/peds.2008-3667.</citation>
    <PMID>19948615</PMID>
  </reference>
  <reference>
    <citation>Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, Chen CA, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008 Jul;122(1):e39-45. doi: 10.1542/peds.2007-2222. Epub 2008 Jun 2.</citation>
    <PMID>18519449</PMID>
  </reference>
  <reference>
    <citation>Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, Huang HJ, Hsu WC, Tsai TH, Hwu WL. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015 Apr;166(4):985-91.e1-2. doi: 10.1016/j.jpeds.2014.10.068. Epub 2014 Nov 4.</citation>
    <PMID>25466677</PMID>
  </reference>
  <reference>
    <citation>Feeney EJ, Austin S, Chien YH, Mandel H, Schoser B, Prater S, Hwu WL, Ralston E, Kishnani PS, Raben N. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun. 2014 Jan 2;2:2. doi: 10.1186/2051-5960-2-2.</citation>
    <PMID>24383498</PMID>
  </reference>
  <reference>
    <citation>Hagemans ML, Hop WJ, Van Doorn PA, Reuser AJ, Van der Ploeg AT. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology. 2006 Feb 28;66(4):581-3.</citation>
    <PMID>16505317</PMID>
  </reference>
  <reference>
    <citation>Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, Van der Ploeg AT. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain. 2005 Mar;128(Pt 3):671-7. Epub 2005 Jan 19.</citation>
    <PMID>15659425</PMID>
  </reference>
  <reference>
    <citation>Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D; Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006 May;148(5):671-676.</citation>
    <PMID>16737883</PMID>
  </reference>
  <reference>
    <citation>Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and management guideline. Genet Med. 2006 May;8(5):267-88. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E].</citation>
    <PMID>16702877</PMID>
  </reference>
  <reference>
    <citation>Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M, DeRiso M, Palmer RE, Ausems MG, Van der Beek NA, Van Diggelen OP, Halley DJ, Van der Ploeg AT, Reuser AJ. Broad spectrum of Pompe disease in patients with the same c.-32-13T-&gt;G haplotype. Neurology. 2007 Jan 9;68(2):110-5.</citation>
    <PMID>17210890</PMID>
  </reference>
  <reference>
    <citation>LaforÃªt P, Laloui K, Granger B, Hamroun D, Taouagh N, Hogrel JY, Orlikowski D, Bouhour F, Lacour A, Salort-Campana E, Penisson-Besnier I, Sacconi S, Zagnoli F, Chapon F, Eymard B, Desnuelle C, Pouget J; French Pompe Registry Study Group. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease. Rev Neurol (Paris). 2013 Aug-Sep;169(8-9):595-602. doi: 10.1016/j.neurol.2013.07.002. Epub 2013 Sep 3.</citation>
    <PMID>24008051</PMID>
  </reference>
  <reference>
    <citation>Rairikar MV, Case LE, Bailey LA, Kazi ZB, Desai AK, Berrier KL, Coats J, Gandy R, Quinones R, Kishnani PS. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T&gt;G &quot;late-onset&quot; GAA variant. Mol Genet Metab. 2017 Nov;122(3):99-107. doi: 10.1016/j.ymgme.2017.09.008. Epub 2017 Sep 19.</citation>
    <PMID>28951071</PMID>
  </reference>
  <reference>
    <citation>Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, Florence JM, Mayhew J, Skrinar A, Corzo D, Laforet P. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve. 2008 Oct;38(4):1236-45. doi: 10.1002/mus.21025.</citation>
    <PMID>18816591</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pompe disease</keyword>
  <keyword>Glycogen Storage Disease Type II</keyword>
  <keyword>Acid Maltase Deficiency</keyword>
  <keyword>Acid Alpha-Glucosidase Deficiency</keyword>
  <keyword>Alglucosidase alfa</keyword>
  <keyword>Newborn Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

